Diclofenac Potassium Powder for Oral Solution [Regulatives / Guidelines]

posted by Ahmed Al Habashi – UAE, 2014-08-16 05:08  – Posting: # 13394
Views: 3,263

I would like to get your advice on the following important matter:

I have received a query from one of MOHs requesting us to justify the absence of BE study for our product “Diclofenac Potassium Powder for Oral Solution” due to presence of Mannitol (890 mg) in the formula.

They mentioned that as per the European BE guidelines, we must conduct a BE study for this product.

Hence, I request you to kindly share your experience related to this matter.

Your response will be highly appreciated.

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,486 posts in 4,135 threads, 1,334 registered users;
online 10 (0 registered, 10 guests [including 6 identified bots]).
Forum time (Europe/Vienna): 20:45 UTC

If you don’t know anything about computers,
just remember that they are machines that do exactly what you tell them
but often surprise you in the result.    Richard Dawkins

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5